Free tool
FAERS Monitor: Ozempic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209637 or its brand name (Ozempic, Semaglutide). Reports on generic versions are filed under their own applications.
Reports
70,721
Serious
35,100
50% of reports
Hospitalization
13,974
Death reported
1,193
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea10,175
- off label use7,482
- vomiting6,675
- diarrhoea6,326
- decreased appetite4,685
- constipation4,636
- weight decreased4,425
- impaired gastric emptying4,024
- product use in unapproved indication3,555
- blood glucose increased3,101
- wrong technique in product usage process3,008
- abdominal pain upper2,957
- fatigue2,956
- headache2,926
- weight increased2,695
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 12 |
| 2017 | 13 |
| 2018 | 1,140 |
| 2019 | 1,589 |
| 2020 | 3,032 |
| 2021 | 3,730 |
| 2022 | 5,301 |
| 2023 | 8,478 |
| 2024 | 12,875 |
| 2025 | 18,612 |
| 2026 | 15,927 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,983,438 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| impaired gastric emptyingSignal | 4,024 | 124.1 | 119.7 | 346,564 |
| constipationSignal | 4,636 | 6.4 | 6.3 | 21,054 |
| decreased appetiteSignal | 4,685 | 6.1 | 5.9 | 19,795 |
| blood glucose increasedSignal | 3,101 | 5.0 | 4.8 | 9,726 |
| weight decreasedSignal | 4,425 | 4.8 | 4.6 | 13,163 |
| wrong technique in product usage processSignal | 3,008 | 4.5 | 4.3 | 8,046 |
| abdominal pain upperSignal | 2,957 | 4.3 | 4.2 | 7,504 |
| product use in unapproved indicationSignal | 3,555 | 4.3 | 4.2 | 9,022 |
| vomitingSignal | 6,675 | 4.3 | 4.2 | 16,843 |
| nauseaSignal | 10,175 | 3.9 | 3.8 | 22,116 |
| weight increasedSignal | 2,695 | 3.6 | 3.5 | 5,077 |
| diarrhoeaSignal | 6,326 | 2.9 | 2.9 | 8,234 |
| off label useSignal | 7,482 | 2.6 | 2.5 | 7,321 |
| headache | 2,926 | 1.4 | 1.3 | 328 |
| fatigue | 2,956 | 1.1 | 1.1 | 45 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.